2025欧洲肿瘤内科学会年会（ESMO Congress 2025）将于欧洲中部夏令时间10月17日-21日在德国柏林举行。7月25日，ESMO官网已公布常规摘要题目及作者信息。
【肿瘤资讯】特此整理了入选Proffered Paper Session与Mini Oral Session的肺癌领域重磅临床研究，带您一睹前沿风采。
Proffered paper session: Non-metastatic NSCLC
摘要号：2757O
Title：Tarlatamab with first-line chemoimmunotherapy for extensive stage small cell lung cancer (ES-SCLC): DeLLphi-303 study
标题：Tarlatamab联合一线化疗免疫疗法治疗广泛期小细胞肺癌（ES-SCLC）：DeLLphi-303研究
讲者：Martin Wermke (Dresden, Germany)
Mini Oral session 1: Non-metastatic NSCLC
摘要号：2758MO
Title：Updated results from a phase 1/2 study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers
标题：gocatamig治疗小细胞肺癌（SCLC）及其他神经内分泌癌的1/2期研究的更新结果
讲者：Himisha Beltran (Boston, United States of America)
摘要号：2759MO
Title： DAREON®-8: a Phase I trial of first-line obrixtamig plus standard of care (SoC) in extensive-stage small cell lung carcinoma (ES-SCLC)
标题：DAREON®-8：一线obrixtamig联合标准治疗（SoC）治疗广泛期小细胞肺癌（ES-SCLC）的I期试验
讲者：Solange Peters (Lausanne, Switzerland)
摘要号：2760MO
Title： Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients (pts) with extensive-stage (ES) small cell lung cancer (SCLC) and baseline (BL) brain metastases (BM): Primary analysis of IDeate-Lung01
标题：Ifinatamab deruxtecan（I-DXd）在广泛期（ES）小细胞肺癌（SCLC）且基线（BL）有脑转移（BM）患者中的颅内活性：IDeate-Lung01的主要分析
讲者：Pedro F. Simoes da Rocha (Barcelona, Spain)
摘要号：2761MO
Title：Chemo-immunotherapy followed by Durvalumab and Ceralasertib in treatment naïve patients with extensive-stage small cell lung cancer
标题：化疗免疫疗法后序贯度伐利尤单抗和Ceralasertib治疗初治广泛期小细胞肺癌
讲者：Muhammad Furqan (Iowa City, United States of America)
摘要号：2762MO
Title：Patterns of disease progression (PD) and efficacy associated with tumour burden from the Phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in ES-SCLC
标题：芦比替定（lurbi）+阿替利珠单抗（atezo）作为一线（1L）维持治疗（tx）在广泛期小细胞肺癌（ES-SCLC）中的疾病进展（PD）模式及与肿瘤负荷相关的疗效：3期IMforte研究
讲者：Luis Paz-Ares (Madrid, Spain)
Mini oral session 2: Non-metastatic NSCLC
摘要号：1787MO
Title：Updated results from the phase III ALINA study of adjuvant alectinib vs chemotherapy (chemo) in patients (pts) with early-stage ALK+ non-small cell lung cancer (NSCLC)
标题：辅助阿来替尼对比化疗（chemo）治疗早期ALK+非小细胞肺癌（NSCLC）患者的3期ALINA研究的更新结果
讲者：Rafal Dziadziuszko (Gdansk, Poland)
摘要号：1817MO
Title：Molecular residual disease (MRD) analysis from the LAURA study of osimertinib (osi) in unresectable (UR) stage III EGFR-mutated (EGFRm) NSCLC
标题：LAURA研究中奥希替尼（osi）治疗不可切除（UR）III期EGFR突变（EGFRm）非小细胞肺癌（NSCLC）的分子残留病灶（MRD）分析
讲者：Edurne Arriola Aperribay (Barcelona, Spain)
摘要号：1818MO
Title：Surgery versus radiotherapy after induction therapy with serplulimab combined with chemotherapy for unresectable stage IIIB-IIIC non-small cell lung cancer: a randomized controlled, open-label, phase 2 trial
标题：不可切除IIIB-IIIC期非小细胞肺癌经斯鲁利单抗联合化疗诱导治疗后手术对比放疗的随机对照、开放标签II期临床试验
讲者：Suyu Wang (中国上海)
Mini oral session 1 : NSCLC metastatic
摘要号：1845MO
Title：Prospective observational study of brigatinib after alectinib in ALK-positive, non-small cell lung cancer: efficacy and biomarker analyses from Cohort A of the WJOG11919L/ABRAID trial
标题：阿来替尼治疗后布格替尼用于ALK阳性非小细胞肺癌的前瞻性观察研究：WJOG11919L/ABRAID试验A队列疗效与生物标志物分析
讲者：Yuichi Ozawa (Wakayama, Japan)
摘要号：1846MO
Title：Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases
标题：第二代KRAS G12C抑制剂Olomorasib在伴活动性未治疗脑转移的KRAS G12C突变NSCLC患者中的颅内疗效
讲者：Philippe Cassier (Lyon, France)
摘要号：1847MO
Title：Activity of Zipalertinib Against Active Central Nervous System (CNS) Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC) Harboring EGFR Exon 20 Insertion (Ex20ins)/Other Uncommon Mutations
标题：Zipalertinib对携带EGFR 20号外显子插入突变/其他不常见突变的非小细胞肺癌患者活动性中枢神经系统（CNS）转移的疗效
讲者：Kadoaki Ohashi (Okayama, Japan)
摘要号：1848MO
Title：Phase 2 Study of Firmonertinib in Patients with Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer (mNSCLC) with EGFR Exon 20 Insertion (Ex20ins) Mutations
标题：伏美替尼治疗经治晚期/转移性非小细胞肺癌（mNSCLC）伴EGFR 20号外显子插入（Ex20ins）突变患者的II期研究
讲者：程颖(Ying Cheng , 吉林省肿瘤医院)
摘要号：1849MO
Title：Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
标题：恩考芬尼联合binimetinib治疗BRAF V600E突变转移性非小细胞肺癌（mNSCLC）患者的2期PHAROS研究的更新总生存分析
讲者：Melissa L. Johnson (Nashville, United States of America, TN)
Mini oral session 2 : NSCLC metastatic
摘要号：1850MO
Title：TeLuRide-005: Phase 2 Study of EIK1001, a Toll-Like Receptor 7/8 (TLR7/8) Co-Agonist with Pembrolizumab (pembro)+Chemotherapy (chemo) as First-Line (1L) Therapy in Stage 4 Non-Small Cell Lung Cancer (NSCLC)
标题：TeLuRide-005：EIK1001（一种Toll样受体7/8[TLR7/8]协同激动剂）联合帕博利珠单抗（pembro）+化疗（chemo）作为4期非小细胞肺癌（NSCLC）一线（1L）治疗的2期研究
讲者：Dan Costin (White Plains, United States of America)
摘要号：1851MO
Title：Pembrolizumab plus chemotherapy (PEM + CT) versus pembrolizumab (PEM) as first-line therapy for advanced NSCLC with PD-L1 tumor proportion score (TPS) ≥50%: Open-label, phase 3, randomized trial (PAULIEN)
标题：帕博利珠单抗联合化疗对比帕博利珠单抗单药一线治疗PD-L1 TPS≥50%晚期NSCLC：开放标签III期随机试验（PAULIEN）
讲者：Ilias Houda (Amsterdam, Netherlands)
摘要号：1852MO
Title：KEYMAKER-U01 Substudy 01A: Investigational Agents + Pembrolizumab (Pembro) And Chemotherapy (Chemo) in Untreated Stage IV Non–Small-Cell Lung Cancer (NSCLC)
标题：KEYMAKER-U01子研究01A：研究药物+帕博利珠单抗+化疗治疗初治IV期非小细胞肺癌
讲者：Charu Aggarwal (Philadelphia, United States of America)
如有错漏之处，敬请留言补充！
ESMO Congress 2025 - Conference Calendar - ESMO Congress 2025
排版编辑：肿瘤资讯-TY
苏公网安备32059002004080号
